Urogenital disorders associated with oestrogen deficiency: The role of promestriene as topical oestrogen therapy

Gynecological Endocrinology

Volumn 26, Issue 9, 2010, Pages 644-651

  Santos, Isabel ^a   Clissold, Steve ^b  

^a CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

^b Content Ed Net ^*  (Spain)

Author keywords

hormone replacement therapy; menopause; Oestrogens; promestriene

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN RECEPTOR; LUBRICATING AGENT; PLACEBO; PROMESTRIENE;

BONE; BREAST CANCER; CLINICAL TRIAL; COGNITION; CREAM; DEMENTIA; DRUG ABSORPTION; DRUG CAPSULE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPAREUNIA; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE SEXUAL DYSFUNCTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MASTALGIA; MENOPAUSE; PERINEUM PAIN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SMOKING; STROKE; TABLET; THROMBOEMBOLISM; URGE INCONTINENCE; URINARY TRACT INFECTION; URINARY URGENCY; UROGENITAL TRACT DISEASE; UTERUS BLEEDING; VAGINA ATROPHY; VAGINA PESSARY; VAGINAL BURNING SENSATION; VAGINAL DRYNESS; VAGINAL PRURITUS; VULVODYNIA;

ADMINISTRATION, TOPICAL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FEMALE UROGENITAL DISEASES; HUMANS; MODELS, BIOLOGICAL;

EID: 77955799732     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513591003767948     Document Type: Review

References (36)

1. Chakraborty TR, Gore AC. Aging-related changes in ovarian hormones, their receptors, and neuroendocrine function. Exp Biol Med 2004;229:977-987.
2. The Practice Committee of the American Society of Reproductive Medicine. Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 2004;82(Suppl. 1):S70-S80.
3. Barlow DH, Cardozo LD, Francis RM, Griffin M, Hart DM, Stephens E, Sturdee DW. Urogenital ageing and its effect on sexual health in older British women. Br J Obstet Gynaecol 1997;104:87-91.
4. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Womens Health Initiative. Maturitas 2004;49:292-303.
5. Al-Baghdadi O, Ewies AAA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-todate overview. Climacteric 2009;12:91-105.
6. Lobo RA, Bélisle S, Creasman WT, Sims JM, Frankel NR, Goodman NF, Hall JE, Ivey SL, Kingsberg Slanger R, et al. Should symptomatic menopausal women be offered hormone therapy? MedGenMed 2006;8:40.
7. Frank JE, Mistretta P, Will J. Diagnosis and treatment of female sexual dysfunction. Am Fam Physician 2008;77:635-642.
8. Nappi RE, Nijland EA. Womens perspective of sexuality around the menopause: outcomes of a European telephone survey. Eur J Obstet Gynecol Reprod Biol 2008;137:10-16.
9. Kao A, Binik YM, Kapuscinski A, Khalifé S. Dyspareunia in postmenopausal women: a critical review. Pain Res Manage 2008;13:243-254.
10. Graziottin A, Rovei V. Sexual pain disorders. In: Tepper MS, Owens AF, editors. Sexual health. Chapter 11. Westport, CT: Greenwood Publishing Group; 2006. pp. 287-312.
11. Dennerstein L, Alexander JL, Kotz K. The menopause and sexual functioning: a review of the population-based studies. Annu Rev Sex Res 2003;14:64-82.
12. Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63:138-141.
13. Gebhardt J, Richard D, Barrett T. Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am J Obstet Gynecol 2001;185:1325-1330.
14. Quinn SD, Domoney C. The effects of hormones on urinary incontinence in postmenopausal women. Climacteric 2009; 12:106-113.
15. Thomas TM, Plymat KR, Blannin J, Meade TW. Prevalence of urinary incontinence. BMJ 1980;281:1243-1245.
16. Burger H, Archer D, Barlow D, Birkhäuser M, Calaf-Alsina J, Gambacciani M, Genazzani A, Hadji P, Iversen OE, Kuhl H, et al. Practical recommendations for hormone replacement therapy in the peri-and postmenopause. Climacteric 2004;7: 210-216.
17. Pines A, Sturdee DW, Birkhäuser M, de Villiers T, Naftolin F, Gompel A, Farmer R, Barlow D, Tan D, Maki P, on behalf of the International Menopause Society. HRT in the early menopause: scientific evidence and common perceptions. Climacteric 2008;11:267-272.
18. Schmidt JW, Wollner D, Curcio J, Riedlinger J, Kim LS. Hormone replacement therapy in menopausal women: past problems and future possibilities. Gynecol Endocrinol 2006; 22:564-577.
19. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;18:CD001500.
20. Johnston SL, Farrell SA, Bouchard C, Farrell SA, Beckerson LA, Comeau M, Johnston SL, Lefebvre G, Papaioannou A. The detection and management of vaginal atrophy. J Obstet Gynaecol Can 2004;26:503-515.
21. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000;92:1054-1064.
22. Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? The Oncologist 2008;13:222-231.
23. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45-52.
24. Thomas JT, Mignot A, Roger M, Guillaume M. Compared absorption of promestriene by vaginal and oral routes in postmenopausal women. Presented at the 9th International Congress of Endocrinology, 30 August-5 September, Nice, France.
25. Wolff J-P, Cachelou R, Guéritée N. Absence of systemic hormonal effects in an oestradiol diether topically active on the vaginal mucosa. Maturitas 1982;4:239-246.
26. Pálácios SJ, Uribe L, Fernandez Villoria E. Local and systemic effects after the intravaginal administration of estrogens (Promestrien) in menopausal women. Presented at the XIth World Congress of Gynaecology and Obstetrics, 15-20 September, Berlin, Germany; 1985.
27. Palacios Gil Antunano S, Peralta J, Mú jica I, Fernandez Villoria E. Assessing estradiol diether systemic effects in premenopausal and postmenopausal women. Presented at the 19th National Congress of Gynecology, 22-24 October, Oviedo, Spain; 1987.
28. Wurch TA, Lumbroso M, Becker J-F. Mise en évidence de labsense deffet systémique du promestriene employé a doses é levées. Gynécologie 1988;39:101-103.
29. Bonneton A, Dechaud H, Fleury MC, Colau JC, Pugeat M. Absence dinfluence du promestriene administré par voie vaginale sur le taux circulant des hormones et des proté ines hépatiques estrogénodé pendantes de la femme ménopausée. Gynécologie 1992;43:45-48.
30. Romanini C, Villani L, Pasqua M, Gaglione R, Fischetti C, Fornara CF. Traitement prolongé de la vaginite atrophique par promestriene. Résultats et tolérance. Gynécologie 1980; 31:627-631.
31. Vors J, Muller P. Trophicité vaginale et Colpotrophine. Méd Gén 1975; 1 November 1.
32. Campana G, Di Francesco G. Sindrome climacteria: esperienze cliniche con il promestriene. Ann Ost Gin Med Perin 1976;97:189-198.
33. Romanini C, Paparatti L, Finelli FG. Activités estrogéniques locales et systémiques de deux topiques vaginaux utilisés dans le traitement des atrophies ménopausiques. Méd Hyg 1986; 44:1562-1568.
34. Baudet J-H, Pichereau D, Daffos F, Marceau B, Eyraud J-P. Therapeutic tests of the application of colpotrophine cream in cases of episiotomy immediately after childbirth. Gazette Med France 1978;85:4941-4942.
35. Sadoul G, Beuret T, Thomas Jl. Healing of the uterine cervix after laser treatment-comparison of course after application of promestriene. Gynécologie 1986;37:332-336.
36. Tinelli A, Malvasi A, DAnna L, Tinelli R, Perrone A, Tinelli FG. Presurgical promestriene therapy in postmenopausal women with stress urinary incontinence. Gynecol Endocrinol 2007;23:445-450.